Abraxane Label Expansion Lifts Celgene
Celgene Corporation ( CELG ) received encouraging news from Europe when the EC cleared its cancer drug, Abraxane, for an additional indication. Abraxane was approved by the EC as a first-line therapy in patients suffering from metastatic adenocarcinoma of the pancreas in combination with Eli Lilly and Company ’s ( LLY ) Gemzar. The positive news on Abraxane impacted the stock positively. […]